Senseonics Holdings, Inc. (SENS)
Nasdaq · Healthcare · Medical Devices
$10.31+4.35%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $545M
- 52-week range
- $4.79 – $11.58
- 52-week change
- −12.57%
- EPS (trailing)
- −$2.23
- Analyst rating
- 2.0 Buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $35.3M (+56.89%)
- Net income
- −$69.1M
- Operating margin
- −193.8%
- Diluted EPS
- −$1.66
- Free cash flow
- −$60.2M
From the company’s annual report on SEC EDGAR.
About Senseonics Holdings, Inc.
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Headquarters: Germantown, United States · 130 employees · senseonics.com